Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Meda Turns Down Mylan's Merger Proposal

April 7, 2014 8:30 am | News | Comments

Swedish drug company Meda has rebuffed an approach from generic drug maker Mylan which was looking to combine the two businesses. Meda AB says talks between the two companies have stopped "without further actions." Read more...       


Daiichi Sankyo Selling Ranbaxy to Sun Pharmaceutical

April 7, 2014 8:25 am | News | Comments

Daiichi Sankyo Co. said Monday it will sell its stake in Indian unit Ranbaxy Laboratories Ltd. to Sun Pharmaceutical Industries Ltd., as the Japanese firm shifts its generic drug business strategy. Read more...           


Mallinckrodt to Buy Questcor for $5.2B

April 7, 2014 8:17 am | News | Comments

Ireland's Mallinckrodt is buying Questcor Pharmaceuticals Inc. for a combination of stock and cash valued at about $5.2 billion, a purchase that will help to diversify Mallinckrodt's business. Read more...         


Plant Nanotubes May Improve Chemotherapy Treatment

April 4, 2014 1:52 pm | News | Comments

Researchers took what some would consider garbage and made a remarkable scientific tool, one that could someday help to correct genetic disorders or treat cancer without chemotherapy’s nasty side effects. Read more...         


Sanaria Malaria Vaccine Wins Excellence Award

April 4, 2014 1:40 pm | News | Comments

Sanaria received the 2014 Vaccine Industry Excellence Award for the "Best Prophylactic Vaccine" at a ceremony held last month in Washington, D.C. during the 14th World Vaccine Congress. Read more...                 


Jammed Protein Signal Forces Cancer Cells to Devour Themselves

April 4, 2014 1:30 pm | News | Comments

Under stress from chemotherapy or radiation, some cancer cells dodge death by consuming a bit of themselves, allowing them to essentially sleep through treatment and later awaken as tougher, resistant disease. Read more...       


Amgen Melanoma Drug Trial Misses OS Endpoint

April 4, 2014 1:22 pm | News | Comments

Amgen announced results from the primary overall survival analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor. Read more...


Arkansas to Ask Court to Reconsider Risperdal Fine

April 4, 2014 1:13 pm | by Andrew DeMillo | News | Comments

Arkansas Attorney General Dustin McDaniel said he plans to ask the state Supreme Court to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson over the marketing of the antipsychotic drug Risperdal. Read more...


Obama Signs $126M Cancer Research Bill

April 4, 2014 1:00 pm | by Nedra Pickler | News | Comments

A 10-year-old Leesburg, Va., girl who died of brain cancer is leaving a legacy for other sick children in a new bipartisan law signed by President Barack Obama. Read more...             


EU Study Reveals New Causes of Mouth, Throat Cancer

April 4, 2014 11:04 am | News | Comments

Poor oral health and failure to have regular dental checks could increase the risk of mouth and throat cancer, according to a pan-European study. Read more...                           


Merck, Ferring, WHO to Advance Temperature-Stable Bleeding Drug

April 4, 2014 10:53 am | News | Comments

Merck, Ferring Pharmaceuticals and the WHO are collaborating to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding in women after childbirth, that is designed to be stable at room temperature, even in hot and tropical climates. Read more...


Nanoparticles Cause Cancer Cells to Self-Destruct

April 4, 2014 10:42 am | Videos | Comments

Using magnetically controlled nanoparticles to force tumor cells to "self-destruct: sounds like science fiction, but could be a future part of cancer treatment, according to new research. Read more...               


Halozyme Halts Pancreatic Cancer Trial

April 4, 2014 10:36 am | News | Comments

Halozyme Therapeutics announced that as a result of a recommendation from an independent Data Monitoring Committee, the company is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial in patients with pancreatic cancer. Read more...


FDA Approves Easy-to-Use Heroin Overdose Antidote

April 4, 2014 10:24 am | by Lauran Neergaard and Mary Clare Jalonick | News | Comments

The FDA approved an easy-to-use device that automatically injects the right dose of an overdose antidote named naloxone before an ambulance arrives, enabling friends and family to take the first step to save a loved one from an overdose before an ambulance arrives. Read more...


New Drug Prevents Tumor Growth by Inhibiting Key Enzyme

April 4, 2014 10:19 am | Videos | Comments

A ground-breaking has shown that fast-growing cancer cells are sensitive towards imbalances in the metabolism of nucleotides, the building blocks of DNA. This vulnerability can be exploited for a radically novel antitumor therapeutic approach. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.